COVID-19大流行对全球细胞病理学实践的影响:23国实验室国际调查
该研究通过国际调查收集23国41家细胞病理实验室在COVID-19封锁4周及2019年同期数据,发现样本总量从190,225例降至104,319例,平均减少45.3%,非妇科样本恶性率增加5.56%(95%CI 3.77%-7.35%),反映癌症高危患者优先就诊。
要点
- 封锁期间细胞学样本总量平均减少45.3%,各解剖部位和标本类型均下降。
- 宫颈阴道、甲状腺和肛直肠样本占比显著降低(P<.05)。
- 非妇科样本恶性率增加5.56%(95%CI 3.77%-7.35%),含可疑类别增加6.95%。
核心结论
- COVID-19大流行导致细胞学标本总量急剧减少,无论解剖部位或标本类型。
- 恶性率增加反映癌症高危患者被优先处理。
- 有必要前瞻性监测封锁期间医疗服务延迟的影响。
研究设计与样本
- 国际调查纳入23国41家细胞病理实验室。
- 收集COVID-19封锁4周及2019年同期实验室活动数据。
- 记录各解剖部位脱落细胞学和细针穿刺细胞学样本数量和百分比。
- 采用荟萃分析方法比较两期恶性率和可疑率差异。
主要发现
- 样本总量从2019年190,225例降至104,319例,平均减少45.3%(范围0.1%-98.0%)。
- 宫颈阴道、甲状腺和肛直肠区域样本百分比显著降低(P<.05)。
- 泌尿道、浆膜腔、乳腺、淋巴结、呼吸道、唾液腺、中枢神经系统、胃肠道、胰腺、肝和胆道样本百分比增加(P<.05)。
- 非妇科样本恶性率总体增加5.56%(95%CI 3.77%-7.35%)。
- 纳入可疑类别后总体增加6.95%(95%CI 4.63%-9.27%)。
关键数值与推荐
- 样本总量:COVID-19封锁期104,319例 vs 2019年同期190,225例。
- 平均样本量减少45.3%(范围0.1%-98.0%)。
- 非妇科样本恶性率增加5.56%(95%CI 3.77%-7.35%)。
- 含可疑类别的恶性率增加6.95%(95%CI 4.63%-9.27%)。
临床怎么用
- 细胞病理实验室应认识封锁期间样本量骤降及恶性率升高的现象。
- 应优先保障癌症高危患者的细胞学检查。
- 需前瞻性监测因封锁导致医疗服务延迟的后续影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To the authors' knowledge, the impact of the coronavirus disease 2019 (COVID-19) pandemic on cytopathology practices worldwide has not been investigated formally. In the current study, data from 41 respondents from 23 countries were reported. METHODS: Data regarding the activity of each cytopathology laboratory during 4 weeks of COVID-19 lockdown were collected and compared with those obtained during the corresponding period in 2019. The overall number and percentage of exfoliative and fine-needle aspiration cytology samples from each anatomic site were recorded. Differences in the malignancy and suspicious rates between the 2 periods were analyzed using a meta-analytical approach. RESULTS: Overall, the sample volume was lower compared with 2019 (104,319 samples vs 190,225 samples), with an average volume reduction of 45.3% (range, 0.1%-98.0%). The percentage of samples from the cervicovaginal tract, thyroid, and anorectal region was significantly reduced (P < .05). Conversely, the percentage of samples from the urinary tract, serous cavities, breast, lymph nodes, respiratory tract, salivary glands, central nervous system, gastrointestinal tract, pancreas, liver, and biliary tract increased (P < .05). An overall increase of 5.56% (95% CI, 3.77%-7.35%) in the malignancy rate in nongynecological samples during the COVID-19 pandemic was observed. When the suspicious category was included, the overall increase was 6.95% (95% CI, 4.63%-9.27%). CONCLUSIONS: The COVID-19 pandemic resulted in a drastic reduction in the total number of cytology specimens regardless of anatomic site or specimen type. The rate of malignancy increased, reflecting the prioritization of patients with cancer who were considered to be at high risk. Prospective monitoring of the effect of delays in access to health services during the lockdown period is warranted.
引用
- Vigliar E, Cepurnaite R, Alcaraz-Mateos E, et al. Global impact of the COVID-19 pandemic on cytopathology practice: Results from an international survey of laboratories in 23 countries. Cancer Cytopathol. 2020. PMID: 33108683. doi:10.1002/cncy.22373
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。